Nishigaki T, Nakamura K, Tanaka M
J Pharmacobiodyn. 1985 Jun;8(6):409-16. doi: 10.1248/bpb1978.8.409.
In vitro decomposition of ACNU, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitros ourea hydrochloride, in various conditions was studied with the use of the 14C-labeled compound. Metabolite A, 3,4-dihydro-7-methylpyrimido[4,5-d]pyrimidin-2(1H)-one (an intramolecular cyclized product), was formed spontaneously in the phosphate buffer (pH 7.4) with simultaneous liberation of the alkylating moiety. With rat liver enzyme preparations, formation of three metabolites was observed. Those were metabolite B, 1-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)urea (a denitrosated product), metabolite C, 1-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-5-hydroxy-3-nitroso-2-imidazolidinone (a product via oxidative dechlorination), and metabolite D, 1-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-hydroxy-2-imidazolidinone (a denitrosated product of metabolite C). Formation of metabolite B was catalyzed with both cytosolic and microsomal enzymes, not inhibited with SKF-525A, and partly dependent on nicotinamide adenine dinucleotide phosphate (NADPH). These results suggest that at least two enzymatic steps would be involved in the formation of this product. Metabolites C and D were produced by the microsomal preparation, being dependent on O2 and NADPH, inhibited by CO and SKF-525A, and enhanced by phenobarbital pretreatment. When metabolite C was incubated with cytosolic and microsomal preparations, more efficient formation of metabolite D with the former than the latter was observed. From these results, it was assumed that oxidative dechlorination of ACNU to metabolite C would be catalyzed with the microsomal mixed function oxidase, and metabolite D would be produced via denitrosation process of metabolite C.
利用14C标记化合物研究了盐酸阿糖胞苷(ACNU,3 - [(4 - 氨基 - 2 - 甲基 - 5 - 嘧啶基)甲基] - 1 - (2 - 氯乙基) - 1 - 亚硝基脲)在各种条件下的体外分解情况。代谢物A,3,4 - 二氢 - 7 - 甲基嘧啶并[4,5 - d]嘧啶 - 2(1H) - 酮(一种分子内环化产物),在磷酸盐缓冲液(pH 7.4)中自发形成,同时释放出烷基化部分。用大鼠肝酶制剂时,观察到形成了三种代谢物。它们是代谢物B,1 - [(4 - 氨基 - 2 - 甲基 - 5 - 嘧啶基)甲基] - 3 - (2 - 氯乙基)脲(一种脱亚硝基产物),代谢物C,1 - [(4 - 氨基 - 2 - 甲基 - 5 - 嘧啶基)甲基] - 5 - 羟基 - 3 - 亚硝基 - 2 - 咪唑烷酮(一种通过氧化脱氯产生的产物),以及代谢物D,1 - [(4 - 氨基 - 2 - 甲基 - 5 - 嘧啶基)甲基] - 5 - 羟基 - 2 - 咪唑烷酮(代谢物C的脱亚硝基产物)。代谢物B的形成由胞质和微粒体酶催化,不受SKF - 525A抑制,部分依赖于烟酰胺腺嘌呤二核苷酸磷酸(NADPH)。这些结果表明,该产物的形成至少涉及两个酶促步骤。代谢物C和D由微粒体制剂产生,依赖于O2和NADPH,受CO和SKF - 525A抑制,苯巴比妥预处理可增强其生成。当代谢物C与胞质和微粒体制剂一起孵育时,观察到前者比后者更有效地形成代谢物D。从这些结果推测,ACNU氧化脱氯生成代谢物C由微粒体混合功能氧化酶催化,代谢物D通过代谢物C的脱亚硝基过程产生。